Modern Diagnosis and Management of Hepatocellular Carcinoma

Jorge A. Marrero, Theodore Welling

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The incidence of hepatocellular carcinoma (HCC) is rising, and the number of patients with HCC is expected to more than double over the next 1 to 2 decades. HCC meets the criteria for establishment of a surveillance program. Patients with cirrhosis, regardless of the cause, are at the highest risk for developing HCC and this is the population in which surveillance should be performed. (Alpha-fetoprotein and hepatic ultrasonography are the currently recommended surveillance tests. If a surveillance test is abnormal, there is a need for a recall test for diagnostic evaluation of HCC. Triple-phase imaging is recommended for evaluation at recall, with MRI being more sensitive and specific. Novel genetic markers can improve the histologic diagnosis of early HCC. The Barcelona staging classification is the best system for determining the prognosis of patients and it is linked to an evidence-based treatment algorithm. Resection, transplantation, and percutaneous ablation are considered curative interventions and are currently applied to about 30% of all patients with HCC.

Original languageEnglish (US)
Pages (from-to)233-247
Number of pages15
JournalClinics in Liver Disease
Volume13
Issue number2
DOIs
StatePublished - May 2009

Fingerprint

Hepatocellular Carcinoma
alpha-Fetoproteins
Genetic Markers
Routine Diagnostic Tests
Ultrasonography
Fibrosis
Transplantation
Liver
Incidence
Population

Keywords

  • Cirrhosis
  • Hepatitis B
  • Hepatitis C
  • Liver cancer
  • Surveillance

ASJC Scopus subject areas

  • Hepatology

Cite this

Modern Diagnosis and Management of Hepatocellular Carcinoma. / Marrero, Jorge A.; Welling, Theodore.

In: Clinics in Liver Disease, Vol. 13, No. 2, 05.2009, p. 233-247.

Research output: Contribution to journalArticle

Marrero, Jorge A. ; Welling, Theodore. / Modern Diagnosis and Management of Hepatocellular Carcinoma. In: Clinics in Liver Disease. 2009 ; Vol. 13, No. 2. pp. 233-247.
@article{cf3dd1da4b814550a73c98b59acf42df,
title = "Modern Diagnosis and Management of Hepatocellular Carcinoma",
abstract = "The incidence of hepatocellular carcinoma (HCC) is rising, and the number of patients with HCC is expected to more than double over the next 1 to 2 decades. HCC meets the criteria for establishment of a surveillance program. Patients with cirrhosis, regardless of the cause, are at the highest risk for developing HCC and this is the population in which surveillance should be performed. (Alpha-fetoprotein and hepatic ultrasonography are the currently recommended surveillance tests. If a surveillance test is abnormal, there is a need for a recall test for diagnostic evaluation of HCC. Triple-phase imaging is recommended for evaluation at recall, with MRI being more sensitive and specific. Novel genetic markers can improve the histologic diagnosis of early HCC. The Barcelona staging classification is the best system for determining the prognosis of patients and it is linked to an evidence-based treatment algorithm. Resection, transplantation, and percutaneous ablation are considered curative interventions and are currently applied to about 30{\%} of all patients with HCC.",
keywords = "Cirrhosis, Hepatitis B, Hepatitis C, Liver cancer, Surveillance",
author = "Marrero, {Jorge A.} and Theodore Welling",
year = "2009",
month = "5",
doi = "10.1016/j.cld.2009.02.007",
language = "English (US)",
volume = "13",
pages = "233--247",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Modern Diagnosis and Management of Hepatocellular Carcinoma

AU - Marrero, Jorge A.

AU - Welling, Theodore

PY - 2009/5

Y1 - 2009/5

N2 - The incidence of hepatocellular carcinoma (HCC) is rising, and the number of patients with HCC is expected to more than double over the next 1 to 2 decades. HCC meets the criteria for establishment of a surveillance program. Patients with cirrhosis, regardless of the cause, are at the highest risk for developing HCC and this is the population in which surveillance should be performed. (Alpha-fetoprotein and hepatic ultrasonography are the currently recommended surveillance tests. If a surveillance test is abnormal, there is a need for a recall test for diagnostic evaluation of HCC. Triple-phase imaging is recommended for evaluation at recall, with MRI being more sensitive and specific. Novel genetic markers can improve the histologic diagnosis of early HCC. The Barcelona staging classification is the best system for determining the prognosis of patients and it is linked to an evidence-based treatment algorithm. Resection, transplantation, and percutaneous ablation are considered curative interventions and are currently applied to about 30% of all patients with HCC.

AB - The incidence of hepatocellular carcinoma (HCC) is rising, and the number of patients with HCC is expected to more than double over the next 1 to 2 decades. HCC meets the criteria for establishment of a surveillance program. Patients with cirrhosis, regardless of the cause, are at the highest risk for developing HCC and this is the population in which surveillance should be performed. (Alpha-fetoprotein and hepatic ultrasonography are the currently recommended surveillance tests. If a surveillance test is abnormal, there is a need for a recall test for diagnostic evaluation of HCC. Triple-phase imaging is recommended for evaluation at recall, with MRI being more sensitive and specific. Novel genetic markers can improve the histologic diagnosis of early HCC. The Barcelona staging classification is the best system for determining the prognosis of patients and it is linked to an evidence-based treatment algorithm. Resection, transplantation, and percutaneous ablation are considered curative interventions and are currently applied to about 30% of all patients with HCC.

KW - Cirrhosis

KW - Hepatitis B

KW - Hepatitis C

KW - Liver cancer

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=65149092819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65149092819&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2009.02.007

DO - 10.1016/j.cld.2009.02.007

M3 - Article

C2 - 19442916

AN - SCOPUS:65149092819

VL - 13

SP - 233

EP - 247

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 2

ER -